Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by ghayeson Nov 05, 2021 3:44pm
304 Views
Post# 34093867

analyst's review.

analyst's review.I am keeping a close eye on the RSI .. possibly a dead cat bounce coming ?

Here's the first paragraph of RJ analyst's take on the latest activity of  PROF.
sorry the formatting won't copy over.
 
RECOMMENDATION Profound Medical (PROF-NASDAQ, SB1) reported 3Q21 results last night with a wide miss on Rev. ($2.5 mln vs. $3.1 mln RJe; $3.5 mln consensus; see our Pre-3Q21 expectations).
So, with this Q’s disappointing revenue, we have taken a moment to reflect on our view of PROF. We have always believed the right way to think about this stock is on an 18-month time horizon, certainly not quarter-to-quarter; however, while our conviction in PROF’s fundamentals remain undiminished, we do owe a mea culpa on the fact that we got the timing of our call wrong by ~1 year(explanationonpg.2). As such, we take this opportunity to adjust our revenue estimates to what we believe is a reasonable baseline that PROF should meet—if not, beat—going forward. As such, we cut our 2022 EV/Rev.-driven target price to $28, but, maintaining our focus on PROF’s exceedingly strong fundamentals, we reiterate our Strong Buy ratin
<< Previous
Bullboard Posts
Next >>